On Tuesday, Tscan Therapeutics Inc (NASDAQ: TCRX) opened lower -6.58% from the last session, before settling in for the closing price of $2.28. Price fluctuations for TCRX have ranged from $1.02 to $6.22 over the past 52 weeks.
Annual sales at Healthcare sector company slipped by -14.41% over the past five years. Company’s average yearly earnings per share was noted -10.49% at the time writing. With a float of $46.42 million, this company’s outstanding shares have now reached $52.47 million.
Tscan Therapeutics Inc (TCRX) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Tscan Therapeutics Inc is 18.20%, while institutional ownership is 59.76%. The most recent insider transaction that took place on May 19 ’25, was worth 1,666,553. In this transaction 10% Owner of this company bought 1,388,794 shares at a rate of $1.20, taking the stock ownership to the 6,746,141 shares. Before that another transaction happened on May 20 ’25, when Company’s 10% Owner bought 1,200,000 for $1.20, making the entire transaction worth $1,440,000. This insider now owns 7,946,141 shares in total.
Tscan Therapeutics Inc (TCRX) Latest Financial update
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.25 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.29) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.32 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -10.49% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.41% during the next five years compared to -14.41% drop over the previous five years of trading.
Tscan Therapeutics Inc (NASDAQ: TCRX) Trading Performance Indicators
Check out the current performance indicators for Tscan Therapeutics Inc (TCRX). In the past quarter, the stock posted a quick ratio of 7.06. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 17.37.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.10, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -1.20 in one year’s time.
Technical Analysis of Tscan Therapeutics Inc (TCRX)
Tscan Therapeutics Inc (NASDAQ: TCRX) saw its 5-day average volume 0.4 million, a negative change from its year-to-date volume of 0.47 million. As of the previous 9 days, the stock’s Stochastic %D was 29.98%.
During the past 100 days, Tscan Therapeutics Inc’s (TCRX) raw stochastic average was set at 62.71%, which indicates a significant increase from 27.87% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.19 in the past 14 days, which was higher than the 0.14 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.97, while its 200-day Moving Average is $1.80. Nevertheless, the first resistance level for the watch stands at $2.24 in the near term. At $2.35, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.42. If the price goes on to break the first support level at $2.06, it is likely to go to the next support level at $1.99. The third support level lies at $1.88 if the price breaches the second support level.
Tscan Therapeutics Inc (NASDAQ: TCRX) Key Stats
There are currently 56,748K shares outstanding in the company with a market cap of 120.87 million. Presently, the company’s annual sales total 2,820 K according to its annual income of -127,500 K. Last quarter, the company’s sales amounted to 3,080 K and its income totaled -36,950 K.
